Cellectis/$CLLS
1D1W1MYTD1Y5YMAX
Capital at risk
About Cellectis
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
- Ticker
- $CLLS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 227
- Headquarters
- Paris, France
- Website
- www.cellectis.com
Cellectis Metrics
BasicAdvanced
$110M
-
-$0.65
2.75
-
Price and volume
Market cap
$110M
Beta
2.75
52-week high
$5.48
52-week low
$1.25
Average daily volume
139K
Financial strength
Current ratio
1.366
Quick ratio
1.336
Long term debt to equity
1.76
Total debt to equity
1.957
Interest coverage (TTM)
-7.18%
Profitability
EBITDA (TTM)
-46.677
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-102.34%
Operating margin (TTM)
-90.87%
Effective tax rate (TTM)
0.53%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-11.67%
Return on equity (TTM)
-94.54%
Valuation
Price to revenue (TTM)
2.377
Price to book
2.36
Price to tangible book (TTM)
2.43
Price to free cash flow (TTM)
-3.373
Free cash flow yield (TTM)
-29.65%
Free cash flow per share (TTM)
-0.448
Growth
Revenue change (TTM)
0.61%
Earnings per share change (TTM)
9.38%
3-year revenue growth (CAGR)
37.11%
10-year revenue growth (CAGR)
-1.51%
3-year earnings per share growth (CAGR)
-30.75%
10-year earnings per share growth (CAGR)
-6.54%
What the Analysts think about Cellectis
Analyst ratings (Buy, Hold, Sell) for Cellectis stock.
Analyst projections of the future price of Cellectis stock.
Cellectis Financial Performance
Revenues and expenses
Cellectis Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cellectis News
AllArticlesVideos
Cellectis Unveils In Vivo Gene-Editing Plans for Severe Lipid Disorders
MarketBeat21 hours ago
CLLS Investors Have Opportunity to Join Cellectis S.A. Fraud Investigation with SBS Law
Business Wire2 weeks ago
Securities Fraud Investigation Into Cellectis S.A. (CLLS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.